Found: 7
Select item for more details and to access through your institution.
Negative regulator NLRC3: Its potential role and regulatory mechanism in immune response and immune-related diseases.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.1012459
- By:
- Publication type:
- Article
Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells.
- Published in:
- Cell & Bioscience, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1186/s13578-019-0312-0
- By:
- Publication type:
- Article
Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
A novel staging system and clinical predictive nomogram for more accurate staging and prognosis of malignant pancreatic intraductal papillary mucinous neoplasms: a population-based study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Tissue‐type plasminogen activator (tPA) homozygous Tyr471His mutation associates with thromboembolic disease.
- Published in:
- MedComm, 2023, v. 4, n. 5, p. 1, doi. 10.1002/mco2.392
- By:
- Publication type:
- Article
High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2019, v. 38, n. 1, p. N.PAG, doi. 10.1186/s13046-019-1209-9
- By:
- Publication type:
- Article
High glucose-upregulated PD-L1 expression through RAS signaling-driven downregulation of PTRH1 leads to suppression of T cell cytotoxic function in tumor environment.
- Published in:
- Journal of Translational Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12967-023-04302-4
- By:
- Publication type:
- Article